Torrent Pharma Q2 profit falls 10%, Dr Reddy's slumps 36% in FY27
Synopsis
Two of India's biggest pharmaceutical names reported sharply lower profits in Q2 FY27 — Torrent Pharma down 9.6% despite 50.8% revenue growth, Dr Reddy's down 36% with EBITDA margins collapsing over 600 basis points. The divergence between operating performance and bottom-line outcomes at Torrent, and broad-based weakness at Dr Reddy's, signals that cost and pricing pressures are reshaping India's pharma earnings landscape this cycle.
Key Takeaways
Torrent Pharmaceuticals net profit fell 9.6% year-on-year to ₹534 crore in Q2 FY27 , down from ₹591 crore .
Torrent revenue from operations surged 50.8% to ₹4,979 crore , but total expenses jumped 70.9% to ₹4,222 crore .
Torrent EBITDA rose 53.8% to ₹1,666 crore ; EBITDA margin improved to 33.5% from 32.8% .
Dr Reddy's Laboratories net profit slumped 36% to ₹913.4 crore from ₹1,426.8 crore in Q2 FY26.
Dr Reddy's EBITDA margin contracted to 20.6% from 26.7% — a compression of over 600 basis points .
Finance costs at Torrent jumped to ₹300 crore from ₹48 crore ; depreciation rose to ₹609 crore from ₹204 crore .
Torrent Pharmaceuticals and Dr Reddy's Laboratories, two of India's largest drugmakers, on Friday, 23 October 2026, reported year-on-year declines in consolidated net profit for Q2 FY27 (quarter ended September 2026), as surging expenses and margin compression eroded gains from otherwise resilient operational activity.
Torrent Pharma: Revenue Soars, Profits Squeezed
Ahmedabad-headquartered Torrent Pharmaceuticals posted a 9.6% year-on-year drop in consolidated net profit to ₹534 crore in Q2 FY27, down from ₹591 crore in the same quarter of the previous fiscal year. The decline came even as revenue from operations surged 50.8% to ₹4,979 crore, up from ₹3,302 crore a year ago — a disconnect that points squarely at the cost side of the ledger.
Total expenses ballooned 70.9% year-on-year to ₹4,222 crore from ₹2,471 crore. Finance costs shot up sharply to ₹300 crore from just ₹48 crore, while depreciation and amortisation expenses climbed to ₹609 crore from ₹204 crore — together accounting for a substantial share of the overall expenditure increase during the quarter.
At the operating level, however, the picture was more encouraging. Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 53.8% year-on-year to ₹1,666 crore, with the EBITDA margin expanding to 33.5% from 32.8% in the year-ago period — signalling that core business operations remained robust despite the bottom-line pressure.
Dr Reddy's: Steeper Profit Slide and Margin Contraction
Dr Reddy's Laboratories reported a sharper earnings deterioration for the same period. Net profit fell 36% year-on-year to ₹913.4 crore, compared with ₹1,426.8 crore in Q2 FY26. Revenue from operations edged down 1.5% to ₹8,671 crore from ₹8,805.1 crore, though the company did register a sequential improvement of 7% quarter-on-quarter.
Operating performance also weakened. EBITDA declined 24.2% year-on-year to ₹1,783 crore from ₹2,351.1 crore, and the EBITDA margin contracted significantly to 20.6% from 26.7% in the corresponding quarter of the previous year — a compression of more than 600 basis points.
Sector Context and What's Driving the Pressure
The twin earnings misses come amid a broader phase of cost inflation affecting Indian pharmaceutical companies, including elevated finance charges linked to capacity expansion and acquisition-related debt, as well as higher depreciation from accelerated capital investment cycles. This is consistent with a wider pattern seen across several large-cap pharma results this earnings season.
Notably, while Torrent's revenue growth was exceptional — driven in part by inorganic additions — the cost structure that accompanied it has not yet normalised. For Dr Reddy's, the top-line softness alongside a steep EBITDA margin fall raises questions about pricing pressure in key markets, particularly the United States, which remains the company's largest revenue contributor.
What to Watch Next
Investor attention will now turn to management commentary on cost rationalisation timelines, US generics pricing trends, and whether sequential improvement in revenue at Dr Reddy's can be sustained into Q3 FY27. For Torrent, the trajectory of finance costs and depreciation normalisation will be closely tracked as a signal of when profitability recovery might materialise.
Point of View
Turning a revenue win into a profit loss — a classic sign of integration or expansion costs yet to be absorbed. Dr Reddy's tells a different and more worrying story: both revenue and EBITDA declined, with margin compression of 600-plus basis points pointing to structural pricing headwinds in the US generics market rather than a one-off cost spike. The sector is navigating a difficult inflection — capex cycles driving up depreciation and debt costs simultaneously, while US generic price erosion continues to bite. Investors will need clarity on when these cost curves flatten before re-rating either stock.
NationPress
23 Oct 2026
Frequently Asked Questions
What were Torrent Pharma's Q2 FY27 results?
Torrent Pharmaceuticals reported a 9.6% year-on-year decline in consolidated net profit to ₹534 crore in Q2 FY27, down from ₹591 crore a year earlier. Revenue from operations surged 50.8% to ₹4,979 crore, but higher expenses — including a jump in finance costs to ₹300 crore from ₹48 crore — weighed on the bottom line.
Why did Dr Reddy's profit fall so sharply in Q2 FY27?
Dr Reddy's Laboratories reported a 36% year-on-year fall in net profit to ₹913.4 crore in Q2 FY27, from ₹1,426.8 crore in the same quarter last year. Both revenue and EBITDA declined, with the EBITDA margin contracting sharply to 20.6% from 26.7%, pointing to margin pressures in key markets including the United States.
How did Torrent Pharma's EBITDA perform despite lower profit?
Despite the net profit decline, Torrent's EBITDA rose 53.8% year-on-year to ₹1,666 crore and its EBITDA margin improved to 33.5% from 32.8%. This indicates that core operating performance remained strong, with the profit dip driven by elevated finance costs and depreciation below the EBITDA line.
What caused the spike in Torrent Pharma's expenses in Q2 FY27?
Total expenses at Torrent Pharmaceuticals rose 70.9% year-on-year to ₹4,222 crore. The biggest drivers were finance costs, which jumped to ₹300 crore from ₹48 crore, and depreciation and amortisation, which increased to ₹609 crore from ₹204 crore — likely reflecting capacity expansion or acquisition-related debt and asset additions.
Did Dr Reddy's show any improvement on a sequential basis?
Yes, Dr Reddy's revenue from operations rose 7% on a sequential (quarter-on-quarter) basis, even though it declined 1.5% year-on-year to ₹8,671 crore. Whether this sequential uptick can be sustained into Q3 FY27 will be a key metric for investors tracking the company's recovery path.
